A single intravitreal injection of 4D-150 helped patients with wet age-related macular degeneration maintain visual acuity for up to 2 years, according to a press release from 4DMT.
The company announced positive results from the phase 1/2 PRISM trial that included three cohorts of patients. The phase 2b group included 30 patients with broad disease activity. The phase 2b subgroup included 15 patients with broad disease activity diagnosed within 6 months of starting the trial. The phase 1/2a cohort included 24 patients with severe, recalcitrant disease activity, according to the release.
The